{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:26:44Z","timestamp":1790803604129,"version":"4.1.0"},"reference-count":78,"publisher":"Bentham Science Publishers Ltd.","issue":"19","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Leptomeningeal disease (LMD) is a rare and lethal manifestation that may occur\nin the advanced stages of solid tumors and hematological malignancies. With advances\nin diagnostic techniques, the detection and confirmation of the presence of LMD\nhave increased. Although its optimal treatment remains a challenge, the use of the intrathecal\nroute for the delivery of novel therapeutics is now considered a promising drug\ndelivery strategy to complement radiation and systemic-based therapies. Although\nmethotrexate, cytarabine, and thiotepa have a long history in the treatment of LMD, other\nmedications have also been shown to be beneficial. In this article, we have reviewed the\neffects of novel medications administered via the intrathecal route for the treatment of\nsolid tumors. We have searched PubMed, Scopus, and Google Scholar databases till the\nend of September 2021 using the following keywords: \u201cleptomeningeal disease\u201d, \u201cleptomeningeal\ncarcinomatosis\u201d, \u201cleptomeningeal metastases\u201d, \u201csolid tumors\u201d, \u201csolid cancers\u201d,\nand \u201cintrathecal\u201d. Our literature findings have uncovered that most studies on\nLMD, which occurs secondary to solid cancers, are available as \u2018case reports\u2019, and few\nclinical trials have been conducted to date. Single-drug (monotherapy) or combination\ndrug therapy, administered via the intrathecal route, especially in metastatic breast and\nlung cancer, has been shown to improve patients' symptoms and overall lifespan, while\nexhibiting a low and acceptable prevalence of side effects. However, judgments\/conclusions\nabout the effectiveness and safety of these drugs still require further clinical evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867330666230508142657","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T01:10:32Z","timestamp":1683594632000},"page":"2732-2750","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Review on the Efficacy and Safety of Intrathecal Administration of\nNovel Medications for Leptomeningeal Metastases in Solid Cancers"],"prefix":"10.2174","volume":"31","author":[{"given":"Fatemeh","family":"Jafari","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Moeini","family":"Nodeh","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine,\nMashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesamoddin","family":"Hosseinjani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Baharara","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajad","family":"Azad","sequence":"additional","affiliation":[{"name":"Student Research Committee, Mashhad University\nof Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Arasteh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Pharmaceutical Sciences, School of\nPharmacy, University of Missouri-Kansas City, Kansas City, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Biotechnology Research Center,\nPharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Applied\nBiomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran"},{"name":"Department\nof Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3340\/jkns.2018.0098","volume":"61","author":"Byun Y.H.","year":"2018","unstructured":"Byun Y.H.; Gwak H.S.; Kwon J.W.; Kim K.G.; Shin S.H.; Lee S.H.; Yoo H.; A novel implantable cerebrospinal fluid reservoir: A pilot study. J Korean Neurosurg Soc  2018,61(5),640-644","journal-title":"J Korean Neurosurg Soc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"116706","DOI":"10.1016\/j.jns.2020.116706","volume":"411","author":"Thakkar J.P.","year":"2020","unstructured":"Thakkar J.P.; Kumthekar P.; Dixit K.S.; Stupp R.; Lukas R.V.; Leptomeningeal metastasis from solid tumors. J Neurol Sci  2020,411,116706","journal-title":"J Neurol Sci"},{"key":"ref=3","author":"Alexis Demopoulos M.","year":"2018","unstructured":"Alexis Demopoulos M.; Paul Brown M.; Treatment of leptomeningeal metastases (carcinomatous meningitis).  2018"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.esmoop.2021.100150","volume":"6","author":"Carausu M.","year":"2021","unstructured":"Carausu M.; Carton M.; Darlix A.; Pasquier D.; Leheurteur M.; Debled M.; Mouret-Reynier M.A.; Goncalves A.; Dalenc F.; Verret B.; Campone M.; Augereau P.; Ferrero J.M.; Levy C.; Fumet J.D.; Lefeuvre-Plesse C.; Petit T.; Uwer L.; Jouannaud C.; Larrouquere L.; Chevrot M.; Courtinard C.; Cabel L.; Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open  2021,6(3),100150","journal-title":"ESMO Open"},{"key":"ref=5","author":"Nguyen T.K.","year":"2020","unstructured":"Nguyen T.K.; Nguyen E.K.; Soliman H.; An overview of leptomeningeal disease. Ann Palliat Med  2020","journal-title":"Ann Palliat Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","volume":"4","author":"Le Rhun E.","year":"2019","unstructured":"Le Rhun E.; Preusser M.; van den Bent M.; Andratschke N.; Weller M.; How we treat patients with leptomeningeal metastases. ESMO Open  2019,4(S2),e000507","journal-title":"ESMO Open"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"Clarke J.L.","year":"2010","unstructured":"Clarke J.L.; Perez H.R.; Jacks L.M.; Panageas K.S.; DeAngelis L.M.; Leptomeningeal metastases in the MRI era. Neurology  2010,74(18),1449-1454","journal-title":"Neurology"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1212\/01.CON.0000413661.58045.e7","volume":"18","author":"Clarke J.L.","year":"2012","unstructured":"Clarke J.L.; Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn)  2012,18(2),328-342","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"e2120040","DOI":"10.1001\/jamanetworkopen.2021.20040","volume":"4","author":"White M.D.","year":"2021","unstructured":"White M.D.; Klein R.H.; Shaw B.; Kim A.; Subramanian M.; Mora J.L.; Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Netw Open  2021,4(8),e2120040","journal-title":"JAMA Netw Open"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","volume":"128","author":"Li Y.","year":"2016","unstructured":"Li Y.; Pan W.; Connolly I.D.; Reddy S.; Nagpal S.; Quake S.; Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol  2016,128,93-100","journal-title":"J Neurooncol"},{"key":"ref=11","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418759618","volume":"11","author":"Pellerino A.","year":"2018","unstructured":"Pellerino A.; Bertero L.; Rud\u00e0 R.; Soffietti R.; Neoplastic meningitis in solid tumors: From diagnosis to personalized treatments. Ther Adv Neurol Disord  2018,11","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=12","first-page":"362","volume":"17","author":"Thomas K.H.","year":"2017","unstructured":"Thomas K.H.; Ramirez R.A.; Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy. Ochsner J  2017,17(4),362-378","journal-title":"Ochsner J"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3389\/fonc.2018.00509","volume":"8","author":"de Oca Delgado M.M.","year":"2018","unstructured":"de Oca Delgado M.M.; Cacho D.B.; Santos Z.J.; Guerrero J.V.; L\u00f3pez M.M.S.; Castro M.E.; M\u00e9ndez-Padilla A.J.; Mej\u00eda P.S.; Reyes M.I.; Guti\u00e9rrez A.A.; Gonz\u00e1lez A.A.; The comparative treatment of intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front Oncol  2018,8,509","journal-title":"Front Oncol"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/BF02710168","volume":"7","author":"Rueda D.A.","year":"2005","unstructured":"Rueda D.A.; Olmos H.D.; Viciana G.R.; Torres S.E.; Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin Transl Oncol  2005,7(6),232-238","journal-title":"Clin Transl Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1177\/1177271917695237","volume":"12","author":"Vergoulidou M.","year":"2017","unstructured":"Vergoulidou M.; Leptomeningeal carcinomatosis in gastric cancer: A therapeutical challenge. Biomark Insights  2017,12","journal-title":"Biomark Insights"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2169\/internalmedicine.55.5129","volume":"55","author":"Yamasaki T.","year":"2016","unstructured":"Yamasaki T.; Fukui H.; Sei H.; Hara K.; Eda H.; Kondo T.; Toyoshima F.; Kono T.; Tozawa K.; Ikehara H.; Tomita T.; Oshima T.; Watari J.; Miwa H.; Efficacy of intrathecal MTX\/Ara-C combined with systemic chemotherapy in a gastric cancer patient with meningeal carcinomatosis. Intern Med  2016,55(6),609-611","journal-title":"Intern Med"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10147-008-0846-3","volume":"14","author":"Yamakawa H.","year":"2009","unstructured":"Yamakawa H.; Ariga H.; Enomoto A.; Netsu S.; Suzuki Y.; Konno R.; Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy. Int J Clin Oncol  2009,14(5),447-451","journal-title":"Int J Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.3748\/wjg.15.5086","volume":"15","author":"Oh S.Y.","year":"2009","unstructured":"Oh S.Y.; Lee S.J.; Lee J.; Lee S.; Kim S.H.; Kwon H.C.; Lee G.W.; Kang J.H.; Hwang I.G.; Jang J.S.; Lim H.Y.; Park Y.S.; Kang W.K.; Kim H.J.; Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases. World J Gastroenterol  2009,15(40),5086-5090","journal-title":"World J Gastroenterol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1200\/OP.20.00146","volume":"16","author":"Huppert L.A.","year":"2020","unstructured":"Huppert L.A.; Melisko M.E.; Glastonbury C.M.; Khanafshar E.; Daud A.I.; Treatment of metastatic melanoma with leptomeningeal disease using intrathecal immunotherapy. JCO Oncol Pract  2020,16(11),757-759","journal-title":"JCO Oncol Pract"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"viii464","DOI":"10.1093\/annonc\/mdy289.057","volume":"29","author":"Glitza I.C.","year":"2018","unstructured":"Glitza I.C.; Rohlfs M.L.; Iqbal M.; Richard J.; Burton E.; Duncan S.; Brown C.; Anderson J.; Hwu P.; Hwu W-J.; Wong M.; Yee C.; Patel S.; Woodman S.; Amaria R.; Diab A.; Tawbi H.; Davies M.; A phase I\/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Ann Oncol  2018,29,viii464","journal-title":"Ann Oncol"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9519","volume":"39","author":"John I.","year":"2021","unstructured":"John I.; Foster A.P.; Haymaker C.L.; Bassett R.L.; Lee J.J.; Rohlfs M.L.; Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J Clin Oncol  2021,39(15)","journal-title":"J Clin Oncol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"Paz-Ares L.","year":"2018","unstructured":"Paz-Ares L.; Luft A.; Vicente D.; Tafreshi A.; G\u00fcm\u00fc\u015f M.; Mazi\u00e8res J.; Hermes B.; \u00c7ay \u015eenler F.; Cs\u0151szi T.; F\u00fcl\u00f6p A.; Rodr\u00edguez-Cid J.; Wilson J.; Sugawara S.; Kato T.; Lee K.H.; Cheng Y.; Novello S.; Halmos B.; Li X.; Lubiniecki G.M.; Piperdi B.; Kowalski D.M.; Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. N Engl J Med  2018,379(21),2040-2051","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","volume":"3","author":"Khoja L.","year":"2015","unstructured":"Khoja L.; Butler M.O.; Kang S.P.; Ebbinghaus S.; Joshua A.M.; Pembrolizumab. J Immunother Cancer  2015,3(1),36","journal-title":"J Immunother Cancer"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"Schmid P.","year":"2020","unstructured":"Schmid P.; Cortes J.; Pusztai L.; McArthur H.; K\u00fcmmel S.; Bergh J.; Denkert C.; Park Y.H.; Hui R.; Harbeck N.; Takahashi M.; Foukakis T.; Fasching P.A.; Cardoso F.; Untch M.; Jia L.; Karantza V.; Zhao J.; Aktan G.; Dent R.; O\u2019Shaughnessy J.; Pembrolizumab for early triple-negative breast cancer. N Engl J Med  2020,382(9),810-821","journal-title":"N Engl J Med"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"e002473","DOI":"10.1136\/jitc-2021-002473","volume":"9","author":"Naidoo J.","year":"2020","unstructured":"Naidoo J.; Schreck K.; Fu W.; Hu C.; Connolly R.; Santa-Maria C.; Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J Immunother Cancer  2020,9(8),e002473","journal-title":"J Immunother Cancer"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41591-020-0918-0","volume":"26","author":"Brastianos P.K.","year":"2020","unstructured":"Brastianos P.K.; Lee E.Q.; Cohen J.V.; Tolaney S.M.; Lin N.U.; Wang N.; Chukwueke U.; White M.D.; Nayyar N.; Kim A.; Alvarez-Breckenridge C.; Krop I.; Mahar M.K.; Bertalan M.S.; Shaw B.; Mora J.L.; Goss N.; Subramanian M.; Nayak L.; Dietrich J.; Forst D.A.; Nahed B.V.; Batchelor T.T.; Shih H.A.; Gerstner E.R.; Moy B.; Lawrence D.; Giobbie-Hurder A.; Carter S.L.; Oh K.; Cahill D.P.; Sullivan R.J.; Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat Med  2020,26(8),1280-1284","journal-title":"Nat Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"100103","DOI":"10.1016\/j.cpccr.2021.100103","volume":"4","author":"Ensign S.P.F.","year":"2021","unstructured":"Ensign S.P.F.; Yancey E.; Anderson K.S.; Mrugala M.M.; Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report. Current Problems in Cancer: Case Reports  2021,4,100103","journal-title":"Current Problems in Cancer: Case Reports"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1517\/14712590903110709","volume":"9","author":"Boland W.K.","year":"2009","unstructured":"Boland W.K.; Bebb G.; Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther  2009,9(9),1199-1206","journal-title":"Expert Opin Biol Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/0973-1482.200596","volume":"12","author":"Jiao S.","year":"2016","unstructured":"Jiao S.; Ju Y.; Wang J.; Sun S.; Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer. J Cancer Res Ther  2016,12(S7),181","journal-title":"J Cancer Res Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-019-05317-6","volume":"177","author":"Figura N.B.","year":"2019","unstructured":"Figura N.B.; Rizk V.T.; Armaghani A.J.; Arrington J.A.; Etame A.B.; Han H.S.; Czerniecki B.J.; Forsyth P.A.; Ahmed K.A.; Breast leptomeningeal disease: A review of current practices and updates on management. Breast Cancer Res Treat  2019,177(2),277-294","journal-title":"Breast Cancer Res Treat"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2165\/00003495-200262010-00008","volume":"62","author":"McKeage K.","year":"2002","unstructured":"McKeage K.; Perry C.M.; Trastuzumab. Drugs  2002,62(1),209-243","journal-title":"Drugs"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"Keefe D.L.","year":"2002","unstructured":"Keefe D.L.; Trastuzumab-associated cardiotoxicity. Cancer  2002,95(7),1592-1600","journal-title":"Cancer"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","volume":"33","author":"Curigliano G","year":"2022","unstructured":"Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol  2022,33(3),321-329","journal-title":"Ann Oncol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/annonc\/mdp019","volume":"20","author":"Ferrario C.","year":"2009","unstructured":"Ferrario C.; Davidson A.; Bouganim N.; Aloyz R.; Panasci L.C.; Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol  2009,20(4),792-795","journal-title":"Ann Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1345\/aph.1P197","volume":"44","author":"Perissinotti A.J.","year":"2010","unstructured":"Perissinotti A.J.; Reeves D.J.; Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother  2010,44(10),1633-1640","journal-title":"Ann Pharmacother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s10549-019-05170-7","volume":"175","author":"Figura N.B.","year":"2019","unstructured":"Figura N.B.; Rizk V.T.; Mohammadi H.; Evernden B.; Mokhtari S.; Yu H.M.; Robinson T.J.; Etame A.B.; Tran N.D.; Liu J.; Washington I.; Diaz R.; Czerniecki B.J.; Soliman H.; Han H.S.; Sahebjam S.; Forsyth P.A.; Ahmed K.A.; Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat  2019,175(3),781-788","journal-title":"Breast Cancer Res Treat"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-018-4684-3","volume":"169","author":"Figura N.B.","year":"2018","unstructured":"Figura N.B.; Long W.; Yu M.; Robinson T.J.; Mokhtari S.; Etame A.B.; Tran N.D.; Diaz R.; Soliman H.; Han H.S.; Sahebjam S.; Forsyth P.A.; Ahmed K.A.; Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: A single institution experience. Breast Cancer Res Treat  2018,169(2),391-396","journal-title":"Breast Cancer Res Treat"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"Zagouri F.","year":"2013","unstructured":"Zagouri F.; Sergentanis T.N.; Bartsch R.; Berghoff A.S.; Chrysikos D.; de Azambuja E.; Dimopoulos M.A.; Preusser M.; Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Res Treat  2013,139(1),13-22","journal-title":"Breast Cancer Res Treat"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","volume":"3","author":"Lu N.T.","year":"2015","unstructured":"Lu N.T.; Raizer J.; Gabor E.P.; Liu N.M.; Vu J.Q.; Slamon D.J.; Barstis J.L.; Intrathecal trastuzumab: Immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer  2015,3(1),41","journal-title":"J Immunother Cancer"},{"key":"ref=40","first-page":"1373","volume":"15","author":"Stemmler H.J.","year":"2006","unstructured":"Stemmler H.J.; Schmitt M.; Harbeck N.; Willems A.; Bernhard H.; L\u00e4ssig D.; Schoenberg S.; Heinemann V.; Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep  2006,15(5),1373-1377","journal-title":"Oncol Rep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1634\/theoncologist.2011-0101","volume":"16","author":"Lombardi G.","year":"2011","unstructured":"Lombardi G.; Zustovich F.; Farina P.; Della Puppa A.; Manara R.; Cecchin D.; Brunello A.; Cappetta A.; Zagonel V.; Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. Oncologist  2011,16(8),1175-1188","journal-title":"Oncologist"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1200\/JCO.1995.13.11.2731","volume":"13","author":"Carmichael J.","year":"1995","unstructured":"Carmichael J.; Possinger K.; Phillip P.; Beykirch M.; Kerr H.; Walling J.; Harris A.L.; Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol  1995,13(11),2731-2736","journal-title":"J Clin Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"Von Hoff D.D.","year":"2013","unstructured":"Von Hoff D.D.; Ervin T.; Arena F.P.; Chiorean E.G.; Infante J.; Moore M.; Seay T.; Tjulandin S.A.; Ma W.W.; Saleh M.N.; Harris M.; Reni M.; Dowden S.; Laheru D.; Bahary N.; Ramanathan R.K.; Tabernero J.; Hidalgo M.; Goldstein D.; Van Cutsem E.; Wei X.; Iglesias J.; Renschler M.F.; Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med  2013,369(18),1691-1703","journal-title":"N Engl J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0169-5002(02)00504-4","volume":"40","author":"Chen Y.M.","year":"2003","unstructured":"Chen Y.M.; Chen M.C.; Tsai C.M.; Perng R.P.; Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis\u2014a case report. Lung Cancer  2003,40(1),99-101","journal-title":"Lung Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00280-007-0601-x","volume":"62","author":"Bernardi R.J.","year":"2008","unstructured":"Bernardi R.J.; Bomgaars L.; Fox E.; Balis F.M.; Egorin M.J.; Lagattuta T.F.; Aikin A.; Whitcomb P.; Renbarger J.; Lieberman F.S.; Berg S.L.; Blaney S.M.; Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol  2008,62(2),355-361","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.21037\/apm-20-2086","volume":"9","author":"Miao Q.","year":"2020","unstructured":"Miao Q.; Zheng X.; Zhang L.; Jiang K.; Wu B.; Lin G.; Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. Ann Palliat Med  2020,9(6),4233-4245","journal-title":"Ann Palliat Med"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.21037\/apm-21-321","volume":"11","author":"Ma Y.","year":"2021","unstructured":"Ma Y.; Liu H.; Zhang M.; Liu B.; Ding Q.; Zhang L.; Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: A case report. Ann Palliat Med  2021,11(4),1533-1541","journal-title":"Ann Palliat Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"Fan C.","year":"2021","unstructured":"Fan C.; Zhao Q.; Li L.; Shen W.; Du Y.; Teng C.; Gao F.; Song X.; Jiang Q.; Huang D.; Jin Y.; Lv Y.; Wei L.; Shi T.; Zhao X.; Gao N.; Jiang Z.; Xin T.; Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-Mutant NSCLC\u2014a prospective, open-label, single-arm phase 1\/2 clinical trial (unique identifier: ChiCTR1800016615). J Thorac Oncol  2021,16(8),1359-1368","journal-title":"J Thorac Oncol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.21037\/apm-19-521","volume":"9","author":"Li H.","year":"2020","unstructured":"Li H.; Lin Y.; Yu T.; Xie Y.; Feng J.; Huang M.; Guo A.; Liu X.; Yin Z.; Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: A case report. Ann Palliat Med  2020,9(4),2341-2346","journal-title":"Ann Palliat Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3389\/fonc.2019.00838","volume":"9","author":"Pan Z.","year":"2019","unstructured":"Pan Z.; Yang G.; Cui J.; Li W.; Li Y.; Gao P.; Jiang T.; Sun Y.; Dong L.; Song Y.; Zhao G.; A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front Oncol  2019,9,838","journal-title":"Front Oncol"},{"key":"ref=51","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920937953","volume":"12","author":"Pan Z.","year":"2020","unstructured":"Pan Z.; Yang G.; He H.; Cui J.; Li W.; Yuan T.; Chen K.; Jiang T.; Gao P.; Sun Y.; Cong X.; Li Z.; Wang Y.; Pang X.; Song Y.; Zhao G.; Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: A phase I\/II study. Ther Adv Med Oncol  2020,12","journal-title":"Ther Adv Med Oncol"},{"key":"ref=52","first-page":"2783","volume":"32","author":"Mazur L.","year":"2012","unstructured":"Mazur L.; Opydo-Chanek M.; Stojak M.; Wojcieszek K.; Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res  2012,32(7),2783-2789","journal-title":"Anticancer Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1200\/JCO.2005.06.053","volume":"23","author":"Blaney S.M.","year":"2005","unstructured":"Blaney S.M.; Balis F.M.; Berg S.; Arndt C.A.S.; Heideman R.; Geyer J.R.; Packer R.; Adamson P.C.; Jaeckle K.; Klenke R.; Aikin A.; Murphy R.; McCully C.; Poplack D.G.; Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J Clin Oncol  2005,23(7),1555-1563","journal-title":"J Clin Oncol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.jocn.2013.09.018","volume":"21","author":"Salgia S.","year":"2014","unstructured":"Salgia S.; Fleming G.F.; Lukas R.V.; Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J Clin Neurosci  2014,21(7),1250-1251","journal-title":"J Clin Neurosci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/1078155213494940","volume":"20","author":"Tran H.C.","year":"2014","unstructured":"Tran H.C.; Gardner S.; Weiner H.L.; Liebes L.F.; Finlay J.L.; Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. J Oncol Pharm Pract  2014,20(3),229-232","journal-title":"J Oncol Pharm Pract"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/0284186X.2012.689857","volume":"52","author":"Martens J.","year":"2013","unstructured":"Martens J.; Venuturumilli P.; Corbets L.; Bestul D.; Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol  2013,52(1),175-178","journal-title":"Acta Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","volume":"19","author":"Stemmler H.J.","year":"2008","unstructured":"Stemmler H.J.; Mengele K.; Schmitt M.; Harbeck N.; Laessig D.; Herrmann K.A.; Schaffer P.; Heinemann V.; Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: A case report. Anticancer Drugs  2008,19(8),832-836","journal-title":"Anticancer Drugs"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.3171\/2015.5.FOCUS15158","volume":"39","author":"Tobin M.K.","year":"2015","unstructured":"Tobin M.K.; Geraghty J.R.; Engelhard H.H.; Linninger A.A.; Intramedullary spinal cord tumors: A review of current and future treatment strategies. Neurosurg Focus  2015,39(2),E14","journal-title":"Neurosurg Focus"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1023\/A:1006499313482","volume":"47","author":"Balmaceda C.","year":"2000","unstructured":"Balmaceda C.; Chemotherapy for intramedullary spinal cord tumors. J Neurooncol  2000,47(3),293-307","journal-title":"J Neurooncol"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/neuonc\/3.4.251","volume":"3","author":"Hassall T.","year":"2001","unstructured":"Hassall T.; Mitchell A.E.; Ashley DMJN-o; arboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature. Neuro Oncol  2001,3(4),251","journal-title":"Neuro Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3171\/jns.1988.69.2.0295","volume":"69","author":"Bell W.O.","year":"1988","unstructured":"Bell W.O.; Packer R.J.; Seigel K.R.; Rorke L.B.; Sutton L.N.; Bruce D.A.; Leptomeningeal spread of intramedullary spinal cord tumors: Report of three cases. J Neurosurg  1988,69(2),295-300","journal-title":"J Neurosurg"},{"key":"ref=62","first-page":"252","volume":"19","author":"Xi W.","year":"2016","unstructured":"Xi W.; Junling L.; Jianping X.; Boyan Y.; Lei Y.; Xiaoming W.; Efficacy and security of intrathecal with methotrexate in the treatment of meningeal carcinomatosis. Zhongguo Fei Ai Za Zhi  2016,19(5),252-256","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1002\/ijc.30214","volume":"139","author":"Pan Z.","year":"2016","unstructured":"Pan Z.; Yang G.; He H.; Zhao G.; Yuan T.; Li Y.; Shi W.; Gao P.; Dong L.; Li Y.; Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study. Int J Cancer  2016,139(8),1864-1872","journal-title":"Int J Cancer"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/0973-1482.98993","volume":"8","author":"Salkade P.R.","year":"2012","unstructured":"Salkade P.R.; Teh A.L.; Methotrexate-induced acute toxic leukoencephalopathy. J Cancer Res Ther  2012,8(2),292-296","journal-title":"J Cancer Res Ther"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3109\/08880019009034321","volume":"7","author":"Cohen IJ","year":"1990","unstructured":"Cohen IJ; Stark B.; Kaplinsky C.; Weitz R.; Matz S.; Lerman P.; Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: A case report and analysis of the literature. Pediatr Hematol Oncol  1990,7(1),79-87","journal-title":"Pediatr Hematol Oncol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1054\/bjoc.2000.1574","volume":"84","author":"Jaeckle K.A.","year":"2001","unstructured":"Jaeckle K.A.; Phuphanich S.; Bent M.J.; Aiken R.; Batchelor T.; Campbell T.; Fulton D.; Gilbert M.; Heros D.; Rogers L.; O\u2019Day S.J.; Akerley W.; Allen J.; Baidas S.; Gertler S.Z.; Greenberg H.S.; LaFollette S.; Lesser G.; Mason W.; Recht L.; Wong E.; Chamberlain M.C.; Cohn A.; Glantz M.J.; Gutheil J.C.; Maria B.; Moots P.; New P.; Russell C.; Shapiro W.; Swinnen L.; Howell S.B.; Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer  2001,84(2),157-163","journal-title":"Br J Cancer"},{"key":"ref=67","first-page":"3394","volume":"5","author":"Glantz M.J.","year":"1999","unstructured":"Glantz M.J.; Jaeckle K.A.; Chamberlain M.C.; Phuphanich S.; Recht L.; Swinnen L.J.; Maria B.; LaFollette S.; Schumann G.B.; Cole B.F.; Howell S.B.; A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res  1999,5(11),3394-3402","journal-title":"Clin Cancer Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"Grossman S.A.","year":"1999","unstructured":"Grossman S.A.; Krabak M.J.; Leptomeningeal carcinomatosis. Cancer Treat Rev  1999,25(2),103-119","journal-title":"Cancer Treat Rev"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11060-014-1486-2","volume":"119","author":"Scott B.J.","year":"2014","unstructured":"Scott B.J.; van Vugt V.A.; Rush T.; Brown T.; Chen C.C.; Carter B.S.; Schwab R.; Fanta P.; Helsten T.; Bazhenova L.; Parker B.; Pingle S.; Saria M.G.; Brown B.D.; Piccioni D.E.; Kesari S.; Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: A retrospective cohort study. J Neurooncol  2014,119(2),361-368","journal-title":"J Neurooncol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4143\/crt.2014.234","volume":"48","author":"Park W.Y.","year":"2016","unstructured":"Park W.Y.; Kim H.J.; Kim K.; Bae S.B.; Lee N.; Lee K.T.; Won J.H.; Park H.S.; Lee S.C.; Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res Treat  2016,48(2),843-847","journal-title":"Cancer Res Treat"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-013-1244-x","volume":"115","author":"Comte A.","year":"2013","unstructured":"Comte A.; Jdid W.; Guilhaume M.N.; Kriegel I.; Piperno-Neumann S.; Dieras V.; Dorval T.; Pierga J.Y.; Cottu P.H.; Mignot L.; Bidard F.C.; Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neurooncol  2013,115(3),445-452","journal-title":"J Neurooncol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"Ferguson S.D.","year":"2019","unstructured":"Ferguson S.D.; Bindal S.; Bassett R.L.; Haydu L.E.; McCutcheon I.E.; Heimberger A.B.; Li J.; O\u2019Brien B.J.; Guha-Thakurta N.; Tetzlaff M.T.; Tawbi H.; Davies M.A.; Glitza I.C.; Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol  2019,142(3),499-509","journal-title":"J Neurooncol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cncr.26709","volume":"118","author":"Raizer J.J.","year":"2012","unstructured":"Raizer J.J.; Rademaker A.; Evens A.M.; Rice L.; Schwartz M.; Chandler J.P.; Getch C.C.; Tellez C.; Grimm S.A.; Pemetrexed in the treatment of relapsed\/refractory primary central nervous system lymphoma. Cancer  2012,118(15),3743-3748","journal-title":"Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1023\/A:1006304424346","volume":"44","author":"Archer G.E.","year":"1999","unstructured":"Archer G.E.; Sampson J.H.; McLendon R.E.; Friedman A.H.; Colvin O.M.; Rose M.; Sands H.; McCullough W.; Fuchs H.E.; Bigner D.D.; Friedman H.S.; Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J Neurooncol  1999,44(3),233-241","journal-title":"J Neurooncol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-05-2094","volume":"12","author":"Gururangan S.","year":"2006","unstructured":"Gururangan S.; Petros W.P.; Poussaint T.Y.; Hancock M.L.; Phillips P.C.; Friedman H.S.; Bomgaars L.; Blaney S.M.; Kun L.E.; Boyett J.M.; Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: A Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res  2006,12(5),1540-1546","journal-title":"Clin Cancer Res"},{"key":"ref=76","first-page":"1183","volume":"5","author":"Sampson J.H.","year":"1999","unstructured":"Sampson J.H.; Archer G.E.; Villavicencio A.T.; McLendon R.E.; Friedman A.H.; Bishop W.R.; Bigner D.D.; Friedman H.S.; Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res  1999,5(5),1183-1188","journal-title":"Clin Cancer Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","volume":"19","author":"Mir O.","year":"2008","unstructured":"Mir O.; Ropert S.; Alexandre J.; Lemare F.; Goldwasser F.; High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol  2008,19(11),1978-1980","journal-title":"Ann Oncol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s10549-011-1417-2","volume":"127","author":"Oliveira M.","year":"2011","unstructured":"Oliveira M.; Braga S.; Passos-Coelho J.L.; Fonseca R.; Oliveira J.; Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat  2011,127(3),841-844","journal-title":"Breast Cancer Res Treat"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230508142657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216660\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230508142657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:56:49Z","timestamp":1714733809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216660\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":78,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230508142657","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}